000952.SZ
广济药业
SZSE · Healthcare · C 制造业 · CN
CNY 6.32
−0.94%Year over year
Reported trailing growth
- Revenue
- +5.2%
- EBITDA
- —
- EBIT
- -45.2%
- EPS
- -43.8%
- Free cash flow
- +171.9%
- Operating cash flow
- +94.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.9%
- EBITDA
- -86.0%
- EBIT
- -39.6%
- Net income
- -37.0%
- EPS
- -38.4%
- Free cash flow
- +116.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026